Global Allogeneic Cell Therapy Manufacturing Market

Report ID : 1194 | Published : 2022-01-19 | Pages: | Format:

The Global Allogeneic Cell Therapy Manufacturing Market is valued at US$ 869.6 Mn in 2021, and it is expected to reach US$ 3424.1 Mn by 2030, with a CAGR of 17 % during a forecast period of 2022-2030. Allogeneic cell therapies involve the transfer of cells from a donor to a patient. Allogeneic cells are collected from various sources, among which blood is the prominent source for allogeneic cells. The small volume of blood comprises many cells that quickly gets multiply.

The key factors driving the growth of the allogeneic cell therapy manufacturing market include the rising elderly population, high prevalence of chronic diseases, the growing demand for personalized treatments, increasing healthcare expenditure, rapid technological advancements in the healthcare sector. Many biopharma companies are collaborating to improve research and development activities in stem cell research, considering the need for allogeneic cell therapies. Likely to propel the growth opportunities for the allogeneic cell therapy manufacturing market in the forthcoming years. For instance, in September 2021, Adaptimmune Therapeutics (UK) partnered with Roche Group member, Genentech, to develop and market allogeneic cell therapies to treat multiple cancer indications.

However, the expensive manufacturing of allogeneic cell therapies and the risks associated with allogeneic cell therapies may hamper the market growth over the forecast period.

The allogeneic cell therapy manufacturing market is classified based on products, scale of operation, and region. By products, the market Induced pluripotent stem cells (iPSC), T-cells and Natural killer (NK) cells, Human pluripotent stem cells (hPSCs), Mesenchymal stem cells (MSC), β-cells, Neurons, Immortalized and engineered cell lines, and Tissue engineered product. The mesenchymal stem cells (MSCS) segment is expected to hold the maximum market share in the coming days due to the increasing R&D activities in stem cell therapies. The market is classified Preclinical Scale Operations, Clinical Scale Operations, and Commercial Scale Operations in terms of scale of operation.

Regionally, the market is studied across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America is estimated to hold the maximum share of the market over the forecast years, followed by Europe owing to the growing patients of chronic diseases and surging R&D activities by key players to develop effective allogeneic cell therapies.

Some of the key players operating in the allogeneic cell therapy manufacturing market are Lonza Group, KBI Biopharma, Inc., Waisman Biomanufacturing, Cell and Gene Therapy Catapult, Thermo Fisher Scientific, Inc., Merck KGaA, Catalent Inc., Oxford Biomedica Plc, Fujifilm Cellular Dynamics, Inc., Wuxi Apptec, Charles River Laboratories International, Inc., The Discovery Labs LLC, ABL, Inc., BioCentriq, Commercializing Living Therapies, and others.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Allogeneic Cell Therapy Manufacturing Market Snapshot

Chapter 4. Global Allogeneic Cell Therapy Manufacturing Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Allogeneic Cell Therapy Clinical Trial/Pipeline Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Product, Estimates & Trend Analysis

5.1. By Products, & Market Share, 2019 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2030 for the following By Products:

5.2.1. Induced pluripotent stem cells (iPSC)

5.2.2. T-cells and Natural killer (NK) cells

5.2.3. Human pluripotent stem cells (hPSCs)

5.2.4. Mesenchymal stem cells (MSC)

5.2.5. β-cells

5.2.6. Neurons

5.2.7. Immortalized and engineered cell lines

5.2.8. Tissue engineered product

Chapter 6. Market Segmentation 2: By Scale of Operation Estimates & Trend Analysis

6.1. By Scale of Operation & Market Share, 2019& 2030

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2030 for the following By Scale of Operation

6.2.1. Preclinical Scale Operations

6.2.2. Clinical Scale Operations

6.2.3. Commercial Scale Operations

Chapter 7. Allogeneic Cell Therapy Manufacturing Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) estimates and forecasts By Products, 2019-2030

7.1.2. North America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) estimates and forecasts By Scale of Operation, 2019-2030

7.1.3. North America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) by country, 2019-2030

7.2. Europe

7.2.1. Europe Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Products, 2019-2030

7.2.2. Europe Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Scale of Operation, 2019-2030

7.2.3. Europe Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) by country, 2019-2030

7.3. Asia Pacific

7.3.1. Asia Pacific Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Products, 2019-2030

7.3.2. Asia Pacific Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Scale of Operation, 2019-2030

7.3.3. Asia Pacific Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) by country, 2019-2030

7.4. Latin America

7.4.1. Latin America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Products, (US$ Million) 2019-2030

7.4.2. Latin America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Scale of Operation, (US$ Million) 2019-2030

7.4.3. Latin America Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) by country, 2019-2030

7.5. Middle East & Africa

7.5.1. Middle East & Africa Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Products, (US$ Million) 2019-2030

7.5.2. Middle East & Africa Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) By Scale of Operation, (US$ Million) 2019-2030

7.5.3. Middle East & Africa Allogeneic Cell Therapy Manufacturing Market revenue (US$ Million) by country, 2019-2030

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles

8.2.1. Lonza Group

8.2.2. KBI Biopharma, Inc.

8.2.3. Waisman Biomanufacturing

8.2.4. Cell and Gene Therapy Catapult

8.2.5. Thermo Fisher Scientific, Inc.

8.2.6. Merck KGaA

8.2.7. Catalent Inc.

8.2.8. Lonza Group

8.2.9. Oxford Biomedica Plc

8.2.10. Fujifilm Cellular Dynamics, Inc.

8.2.11. Wuxi Apptec

8.2.12. Charles River Laboratories International, Inc.

8.2.13. The Discovery Labs LLC

8.2.14. ABL, Inc.

8.2.15. BioCentriq

8.2.16. Commercializing Living Therapies

8.2.17. Other Prominent Players

Global Allogeneic Cell Therapy Manufacturing Market, by Products, 2019-2030 (Value US$ Mn)

  • Induced pluripotent stem cells (iPSC)
  • T-cells and Natural killer (NK) cells
  • Human pluripotent stem cells (hPSCs)
  • Mesenchymal stem cells (MSC)
  • β-cells
  • Neurons
  • Immortalized and engineered cell lines
  • Tissue engineered product

Global Allogeneic Cell Therapy Manufacturing Market, by Scale of Operation, 2019-2030 (Value US$ Mn)

  • Preclinical Scale Operations
  • Clinical Scale Operations
  • Commercial Scale Operations

Global Allogeneic Cell Therapy Manufacturing Market, by Region, 2019-2030 (Value US$ Mn)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North America Allogeneic Cell Therapy Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)

  • U.S.
  • Canada

Europe Allogeneic Cell Therapy Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific Allogeneic Cell Therapy Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Allogeneic Cell Therapy Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Allogeneic Cell Therapy Manufacturing Market, by Country, 2019-2030 (Value US$ Mn)

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

 

Competitive Landscape

  • Company Overview
  • Financial Performance
  • Key Development

Latest Strategic Developments

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients